Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in the metadata) for the month of December 2022. The filing, dated January 5, 2023, serves to incorporate by reference a press release issued on December 23, 2022 (Exhibit 99.1). The registrant is a foreign private issuer based in Mechelen, Belgium, filing under Form 20-F.
Financial Metrics
The provided filing text contains no financial data. It is a procedural filing solely designed to distribute a press release. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The filing text does not disclose specific material changes to financial performance or operations. It only confirms the issuance of a press release on December 23, 2022. The content of that press release is not included in the provided text.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, or specific risk factors. It references the incorporation of the press release into various Registration Statements on Form S-8 but does not summarize the substance of that release.
Key Facts for Investor Verification
- Company Identity: Verify that the filing pertains to Galapagos NV, not Lakefront Biotherapeutics NV.
- Missing Content: The actual news or material event is contained in Exhibit 99.1, which is referenced but not included in the provided text.
- Financial Data: No financial metrics are available in this specific filing; investors must consult the company's most recent Form 20-F or quarterly reports for financial status.
- Reference Documents: The press release is incorporated by reference into multiple Form S-8 registration statements (File Nos. 333-204567 through 333-268756).